It's not often that you see a set of preclinical data influence a company's stock price, but Hollis-EdenÂ was feeling a strong wind in its sails when it released its data on HE3235 for prostate cancer. Researchers for the company demonstrated that the therapy stopped the growth of hormone independent tumors in a preclinical model using human tumor cells. And they presented information suggesting that the treatment triggers cell death--a key mechanism in fighting cancer.
This was all welcome news for the company, which saw its stock price jump about 35 percent on the report. Hollis-Eden has been staging a comeback since the U.S. government cut it out of the loop for a BioShield contract. Investors seem ready to believe that the company can do it. Hollis-EdenÂ was recently feature in our weekly columnÂ on emerging drug developers.
- see the dataÂ from Hollis-Eden
- here's the report from TheStreet
Hollis-Eden skyrockets on preclinical cancer data. Report
Hollis-Eden to chop work force in restructuring. Report
Hollis-Eden shares plunge on HHS drug rejection. Report